Nuvisan receives $25M Gates Foundation grant for non-hormonal contraceptive drug discovery

What's the deal? NuvisanDealroom has a profile for this one. Try Dealroom →, a German drug discovery company, has received a $25 million grant from the Gates Foundation to advance a portfolio of non-hormonal contraceptive candidates. The three-year grant will fund the progression of multiple projects through preclinical development, including pushing one lead project toward candidate nomination.

Why now? The grant builds on three years of prior work between Nuvisan and the Gates Foundation. Assets and results generated during the initial funding period are now ready for the next stage of preclinical development.

The programme will also establish an advanced in vitro assay platform to accelerate drug discovery in the field. Nuvisan is collaborating with research teams within the Contraceptive Drug Accelerator (CoDA), a broader network coordinated by the Gates Foundation.

"Non-hormonal contraception remains an important area of research with substantial unmet need," said Dr Martin Lange, executive vice president of therapeutic research at Nuvisan.

What could go wrong? Non-hormonal contraceptive research has historically struggled to translate promising lab results into approved drugs. Preclinical drug discovery is inherently risky — most candidates fail before reaching human trials. The field remains early-stage, with no widely available non-hormonal contraceptive pill on the market yet.

The signal: Nuvisan is a mature drug discovery company with an established track record in women's health, making it an unusual recipient of philanthropic grant funding typically directed at earlier-stage organisations. The $25 million commitment underscores how non-hormonal contraception — a field with clear demand but limited commercial incentive — increasingly depends on mission-driven capital from funders like the Gates Foundation to bridge the gap between academic research and clinical development.

Read more: bionity.com